EMBO Reports· 2026Q1
Coenzyme A activates TLR4 and enhances alternative macrophage activation in line with MyD88 agonism
- 0citations
- Q1SCImago
- 2026year
Short summary
Exogenous coenzyme A (CoA) acts as a weak TLR4 agonist, priming macrophages for enhanced IL-4 signaling and alternative activation, leading to inflammation resolution.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Metabolites and metabolic cofactors can shape the innate immune response, though the pathways by which these molecules adjust inflammation remain incompletely understood. Here we show that the metabolic cofactor coenzyme A (CoA) enhances IL-4 driven alternative macrophage activation [M(IL-4)] in vitro and in vivo. Unexpectedly, we find that perturbations in intracellular CoA metabolism do not influence M(IL-4) differentiation. Rather, we discover that exogenous CoA is a weak TLR4 agonist which primes macrophages for increased receptivity to IL-4 signals and resolution of inflammation via MyD88. Mechanistic studies reveal MyD88-linked signals enhance IL-4 responsiveness, in part, by reshaping chromatin accessibility to enhance transcription of IL-4-linked genes. The results identify CoA as a host metabolic co-factor that influences macrophage function through an extrinsic TLR4-dependent mechanism and suggest that damage-associated molecular patterns (DAMPs) can prime macrophages for alternative activation and resolution of inflammation.
The authors' abstract, as published at the source. EMBO Reports, 2026 · DOI ↗
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Neurology (Neuroscience)
NeurologyNeuroscience